Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with…
Articles by Marisa Wexler, MS
More than half of people with pulmonary arterial hypertension (PAH) who start daily treatment with oral Opsumit (macitentan)…
Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary…
Among people with chronic thromboembolic pulmonary hypertension (CTEPH), risk assessments and treatment patterns prior to surgical procedures do not…
Levels of the protein TXNRD1 are reduced in the blood of people with idiopathic pulmonary arterial hypertension (IPAH), suggesting…
The U.S. Food and Drug Administration (FDA) has approved LungFit PH, Beyond Air‘s device to administer nitric oxide therapy,…
Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in…
Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH),…
The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve…
Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Combining measures of symptom severity, physical function, and heart health can help predict survival outcomes in pulmonary arterial hypertension…